
Monday, September 19, 2016 4:57:37 PM
In My Own Personal Opinion Of Course!

Liked By
Spread the love. Be the first to like this post!
Recent PTN News
- Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's Oral Formulation of PL8177 Demonstrating Therapeutic Effects in Inflammatory Bowel Disease • PR Newswire (US) • 03/02/2023 12:30:00 PM
- Palatin Issued Patent on Vyleesi® (Bremelanotide Injection) For Hypoactive Sexual Desire Disorder in Patients With Controlled Hypertension • PR Newswire (US) • 02/28/2023 12:30:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 02/15/2023 01:27:30 PM
- Palatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update • PR Newswire (US) • 02/15/2023 12:30:00 PM
- Quarterly Report (10-q) • Edgar (US Regulatory) • 02/14/2023 09:50:20 PM
- Statement of Ownership (sc 13g) • Edgar (US Regulatory) • 02/14/2023 06:20:30 PM
- Palatin to Report Second Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on February 15, 2023 • PR Newswire (US) • 02/10/2023 12:30:00 PM
- Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease • PR Newswire (US) • 01/19/2023 12:30:00 PM
- Palatin Receives $4.7 Million of Non-Dilutive Funding • PR Newswire (US) • 01/18/2023 12:30:00 PM
- Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions • PR Newswire (US) • 01/10/2023 12:30:00 PM
- Palatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi® Product Sales Results • PR Newswire (US) • 01/05/2023 12:30:00 PM
- Amended Statement of Changes in Beneficial Ownership (4/a) • Edgar (US Regulatory) • 12/28/2022 03:30:29 PM
- Amended Statement of Changes in Beneficial Ownership (4/a) • Edgar (US Regulatory) • 12/28/2022 03:30:23 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 12/23/2022 10:31:40 PM
- Ladenburg Thalmann & Co. Sticks to Their Buy Rating for Palatin Technologies (PTN) • TipRanks • 11/15/2022 12:05:42 PM
- Quarterly Report (10-q) • Edgar (US Regulatory) • 11/14/2022 09:51:21 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/14/2022 01:02:39 PM
- Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update • PR Newswire (US) • 11/14/2022 12:30:00 PM
- Palatin to Report First Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on November 14, 2022 • PR Newswire (US) • 11/09/2022 10:16:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/02/2022 09:08:25 PM
- Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) • Edgar (US Regulatory) • 11/02/2022 02:37:31 PM
- Palatin Announces $10 Million Registered Direct Offering • PR Newswire (US) • 10/31/2022 01:30:00 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 10/25/2022 09:02:40 PM
- Palatin Presents PL8177 Data at American College of Gastroenterology Annual Meeting • PR Newswire (US) • 10/24/2022 09:32:00 PM
- First Patient Enrolled in Palatin's Phase 2 study of PL8177 in Ulcerative Colitis Trial • PR Newswire (US) • 10/20/2022 11:30:00 AM
FEATURED Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer's Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Disorders Conference • Mar 31, 2023 7:07 AM
ILUS Confirms Further Funding Arrangements and Note Settlement • ILUS • Mar 31, 2023 10:21 AM
Sigyn Therapeutics Announces Filing of 2022 Annual Report on SEC Form 10-K • SIGY • Mar 31, 2023 10:06 AM
ARway Secures Multiple New SDK Deals to Drive Growth in $44B Indoor Positioning and Navigation Market • ARWYF • Mar 30, 2023 10:30 AM
Nextech3D.ai Enters Asian Market with Major 3D Modeling Deal to Revolutionize E-Commerce • NTAR • Mar 30, 2023 10:00 AM
OMID Posts 2022 Annual Report and Provides Update • OMID • Mar 30, 2023 9:15 AM